Boston Scientific Corp. (NYSE:BSX) will abandon its flagship headquarters in Natick, Mass., along Route 9, moving its headquarters to Marlborough, where the medical device giant already has operations.
Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive agreement to acquire Vessix Vascular, Inc., a privately held company based in Laguna Hills, California. Vessix Vascular has developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension. The acquisition is expected to close by the end of November 2012.
October 26, 2012—Terumo Interventional Systems (Somerset, NJ) announced the nationwide availability of its new Pinnacle Precision Access System, which is designed for smooth, efficient, and reliable vascular access. The Pinnacle Precision Access System features a tapered introducer needle to minimize vessel trauma, dilate the tissue, and gain more precise access in difficult cases, such as those impeded by scar tissue or calcification. The device eliminates the need for both a micropuncture kit and a standard size introducer sheath.
Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note.
Kona Medical has announced the initiation of the first clinical study of its device therapy for drug-resistant hypertension. The Kona Surround Sound system utilises focused ultrasound, delivered from outside the body, to treat the nerves leading to and from the kidney.
Medtronic announced on 22 October new results from Symplicity HTN-1, the longest running clinical trial investigating the safety and efficacy of renal denervation. These data showed patients who received renal denervation treatment with the Symplicity system experienced a mean blood pressure reduction of -29/-14mm Hg (p<0.01) at 24 months (n=105).
October 22, 2012—The results of a matched-pair comparison of patients with metastatic colorectal cancer predominantly affecting the liver, for whom all chemotherapy options had been exhausted, showed that the addition of radioembolization using SIR-Spheres (Sirtex Medical Limited, Sydney, Australia) significantly prolonged survival compared to best supportive care (BSC) alone. Ricarda Seidensticker, MD, et al published the study in Cardiovascular and Interventional Radiology (2012;35:1066–1073).
LAGUNA HILLS, Calif., Oct. 22, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year s Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami.
Circumferential ultrasound heating is potentially a more uniform and effective method for performing renal denervation than radiofrequency systems, Marc Sapoval, Department of Cardiovascular Radiology, European Hospital Georges Pompidou, Paris, France, told delegates at the CIRSE annual meeting (15–19 September, Lisbon, Portugal).
Sirtex Medical has announced the treatment of the first patients in Latin America with its SIR-Spheres microspheres used in the treatment of inoperable liver tumours. The first procedure took place on 10 October at the Hospital Italiano de Buenos Aires, Argentina, which is the first centre to offer the therapy in Latin America.
The US Food and Drug Administration has given 510(k) clearance to Surefire Medical for its line of Surefire Angiographic Catheters. Surefire Medical will launch these products in the United States later this year.
ALBANY, N.Y. and NORWELL, Mass., Oct. 8, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (ANGO), a leading provider of innovative minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today it has entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices for the removal of thrombus, or blood clots, from occluded blood vessels.
MINNEAPOLIS - October 3, 2012 - Medtronic, Inc. (NYSE: MDT) announced today that it has successfully completed the first phase of the feasibility study of its next-generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radio-frequency (RF) generator. A total of nine patients were treated with a 100 percent acute success rate in accessing the vessels and delivering therapy. The investigational next-generation Symplicity(TM) system is not commercially available anywhere in the world.
MINNEAPOLIS - October 3, 2012 - Medtronic, Inc. (NYSE: MDT) announced today that it has successfully completed the first phase of the feasibility study of its next-generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radio-frequency (RF) generator. A total of nine patients were treated with a 100 percent acute success rate in accessing the vessels and delivering therapy. The investigational next-generation Symplicity(TM) system is not commercially available anywhere in the world.
On 3 September, Medtronic announced that it has successfully completed the first phase of the feasibility study of its next generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radiofrequency (RF) generator.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos